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of Malassezia induced inflammation. The exposure 
of human antigen-presenting cells (APCs) to differ-
ent clinical isolates of Malassezia strains resulted in 
secretion of significant amounts of proinflammato-
ry cytokine IL-1b. When APCs were pre-treated with 
Z-VAD, a pan-caspase inhibitor, the release of IL-1b 
upon stimulation with Malassezia was abrogated. 
This suggests that Malassezia-induced IL-1b secre-
tion is dependent on inflammasome activation, 
the latter requiring caspase-1 activation. To eluci-
date which type of inflammasome is activated, we 
generated cells deficient for NLRP3 or NLRP1. IL-1b 
release was absent in ce lls lacking NLRP3, where-
as NLRP1-deficiency did not affect IL-1b secretion 
upon Malassezia exposure. Our findings indicate 
that Malassezia is a potent inducer of inflammatory 
response which is mediated through the NLRP3-
inflammasome
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Since their introduction TNF-α antagonists play a 
major role in the treatment of autoimmune disor-
ders like psoriasis, rheumatoid arthritis, ankylosing 
spondylitis, Crohn’s disease and others. Probably 
due to their immunologic nature, these drugs some-
times produce puzzling cutaneous side effects that 
are the subject of this investigation. For instance, 
although TNF-α antagonists are used to treat pso-
riasis, they can produce paradoxical skin inflamma-
tion in a small fraction of patients that can clinically 
resemble psoriasis, dermatitis and other conditions. 
Of 21 patients (13 female, av. 48 years), 47% had a 
reaction either to infliximab and adalimumab or 
both (1 patient) and 6% had a reaction to etaner-
cept. Clinical features as well immunohistochemis-
try for TNF-α, INF-α, IL-1β, IL-22, IL-6, IL-17, CD123. 
IL33, MXA, IL-8 and IL-36α were performed. In each 
patient two histologic samples were taken and 
were evaluated by a grading system from + to ++++ 
(weak, medium, strong and highly active signal) as 
well as +/- (indifferent) and – (negative). Control 
stainings were performed at plaque psoriasis sam-
ples. 
IL-33 was expressed in 86.1% of psoriasis-like or pus-
tular reactions (PPR) but only in 55.6% of dermatitis-
like reactions (DLR) (p = 0.009, Fisher exact test). IL-1 
β was expressed in both PPR and in DLR in 63.9% 
(not significant = n.s.). IL-22 was expressed in 100% 
of PPR and in 97.2% of DLR (n.s.). IL-6 was expressed 
in 58.3% of PPR and in 61.1% of DLR (n.s.). IL-17 was 
expressed in 88.9% of PPR and in 94.4% of DLR (n.s.). 
CD123 was expressed in 44.4% of PPR and in 36.1% 
of DLR (n.s.). TNF-α was expressed in 88.9% of PPR 
and in 86.1% of DLR (n.s.). IFN-α was expressed in 
91.7% of PPR and in 97.2% of DLR (n.s.). MXA was 
expressed in 83.3% of PPR and in 80.6% of DLR (n.s.). 
IL-8 was expressed in 77.8% of PPR and in 83.3% of 
DLR (n.s.). IL-36α was expressed in 66.7% of PPR and 
in 52.8% of DLR (n.s.).
The alarmin IL-33 is a member of the IL-1 family and 
is overexpressed in plaque psoriasis. In histologic 
samples of reactions to TNF- α antagonists, we de-
tected a differential expression of IL-33 in PPR but 
less so in DLR. Further investigations will define the 
role of this cytokine in these rare cutaneous side ef-
fects of anti-TNF-α inhibitor therapy
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Background: Lichen planus (LP) is a relatively com-
mon immunological disorder of the stratified squa-
mous epithelium that affects one to two percent 
of the general adult population. The oral mucosa is 
involved in up to eighty percent of patients (twenty-
five percent mucosal involvement only).
Conventional oral retinoids (Acitretin, Etretinat, 
Isotretinoin and Tretinoin) are listed as evidence 
based treatment recommendations for LP. In com-
parison, Alitretinoin has shown to have additional 
anti-inflammatory effects and less mucocutaneous 
side effects, which could favorably impact this dis-
ease and thereby support patient compliance as 
well. Alitretinoin was not yet systematically investi-
gated in mucosal lichen planus.
Methods: This is a single center, prospective, open 
label, single arm pilot study investigating the effica-
cy and safety of oral Alitretinoin in twenty patients 
suffering from severe oral mucosal lichen planus 
(MLP). Patients are treated with Alitretinoin thirty 
miligramms once daily for twenty-four weeks with a 
follow up of another twenty-four weeks. The prima-
ry objective is to determine the efficacy of Alitreti-
noin in reducing signs and symptoms of severe MLP 
with respect to the proportion of responders based 
on the ‘scoring system for mucosal disease severity 
with special reference to oral lichen planus’ devel-
oped by Escudier et al, Visual Analog Scales (VAS) for 
pain and pruritus and the Oral Health Impact Profile. 
Further assessment is done to investigate the in-
flammatory infiltrate in mucosa and skin before and 
during Alitretinoin therapy by histopathology taken 
before and four weeks after initiation of study treat-
ment with regular hematoxylin and eosin staining 
and different immunohistochemistry.
Results: Four of a total of nine so far included pa-
tients have finished twenty-four weeks of treatment 
with Alitretinoin. In all four patients a reduction in 
disease severity measured by the Escudi er score 
was apparent. Four of the remaining five patients 
have a decreased Escudier score under treatment at 
the actual follow up visits. One patient discontinued 
therapy after twelve weeks because of treatment 
failure. The following adverse events were observed: 
headache and mucosal dryness (eyes, mouth).
Conclusions: The clinical data suggest Alitretinoin to 
be effective in patients with chronic MLP. The study 
is ongoing. Please contact Dr. Kunz if you supervise 
patients with extensive MLP.
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